Author:
AlRuwaili Raed,Al-kuraishy Hayder M.,Alruwaili Mubarak,Khalifa Amira Karam,Alexiou Athanasios,Papadakis Marios,Saad Hebatallah M.,Batiha Gaber El-Saber
Abstract
AbstractAcute ischemic stroke (AIS) is a focal neurological disorder that accounts for 85% of all stroke types, due to occlusion of cerebral arteries by thrombosis and emboli. AIS is also developed due to cerebral hemodynamic abnormality. AIS is associated with the development of neuroinflammation which increases the severity of AIS. Phosphodiesterase enzyme (PDEs) inhibitors have neuro-restorative and neuroprotective effects against the development of AIS through modulation of the cerebral cyclic adenosine monophosphate (cAMP)/cyclic guanosine monophosphate (cGMP)/nitric oxide (NO) pathway. PDE5 inhibitors through mitigation of neuroinflammation may decrease the risk of long-term AIS-induced complications. PDE5 inhibitors may affect the hemodynamic properties and coagulation pathway which are associated with thrombotic complications in AIS. PDE5 inhibitors reduce activation of the pro-coagulant pathway and improve the microcirculatory level in patients with hemodynamic disturbances in AIS. PDE5 inhibitors mainly tadalafil and sildenafil improve clinical outcomes in AIS patients through the regulation of cerebral perfusion and cerebral blood flow (CBF). PDE5 inhibitors reduced thrombomodulin, P-selectin, and tissue plasminogen activator. Herein, PDE5 inhibitors may reduce activation of the pro-coagulant pathway and improve the microcirculatory level in patients with hemodynamic disturbances in AIS. In conclusion, PDE5 inhibitors may have potential roles in the management of AIS through modulation of CBF, cAMP/cGMP/NO pathway, neuroinflammation, and inflammatory signaling pathways. Preclinical and clinical studies are recommended in this regard.
Graphical abstract
Funder
Private Universität Witten/Herdecke gGmbH
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Clinical Biochemistry,Molecular Biology,General Medicine
Reference108 articles.
1. Lugnier C, Al-Kuraishy HM, Rousseau E (2021) PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking. Biochem Pharmacol 185:114431
2. Al-Kuraishy HM, Al-Gareeb AI, Al-Niemi MS, Al-Buhadily AK, Al-Harchan NA, Lugnier C (2020) COVID-19 and phosphodiesterase enzyme type 5 inhibitors. J Microsc Ultrastruct 8(4):141
3. Paes D, Schepers M, Rombaut B, van den Hove D, Vanmierlo T, Prickaerts J (2021) The molecular biology of phosphodiesterase 4 enzymes as pharmacological targets: an interplay of isoforms, conformational states, and inhibitors. Pharmacol Rev 73(3):1016–1049
4. Wood ER, Bledsoe R, Chai J, Daka P, Deng H, Ding Y et al (2015) The role of phosphodiesterase 12 (PDE12) as a negative regulator of the innate immune response and the discovery of antiviral inhibitors. J Biol Chem 290(32):19681–19696
5. Schudt C, Hatzelmann A, Beume R, Tenor H (2011) Phosphodiesterase inhibitors: history of pharmacology. Phosphodiesterases as drug targets. Springer, Heidelberg, pp 1–46
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献